Loading
HeartBeam, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 24 Apr 2026.
HeartBeam, Inc.: what insiders have been doing
HeartBeam, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 18 filings signed by 11 insiders.
On the market, 8 insiders bought (9 purchases totalling €807k) while 2 insiders sold (2 sales totalling €837k). Netting one side against the other leaves €30k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a sale of €762k by Strome Mark e, published on 22 December 2025. Those buying include 6 senior executives, 1 finance chief and 1 chief executive.
The data flag 9 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The clock since the last published purchase (24 April 2026) now reads 177 days. Typically, a trade is published a median of 39 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
Across the 5,811 companies tracked on its exchange, the median is 19 filings; at 18 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 12 purchases and 12 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -21.0 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
70
Thresholds
n/a
Buy Volume
€898,521
12 ops. · all time
Sell Volume
€895,867
12 ops. · all time
Who traded when
BuySaleRichard Ferrari3 buys
Mark E. Strome1 buy1 sale
Tim Cruickshank2 buys
Branislav Vajdic1 buy
George de Urioste1 sale
Marga Ortigas-Wedekind1 buy
+3 other insiders
Since the insiders bought
- -41.8%Entry US$0.88 · Close at T+90 US$0.51
- -37.5%Entry US$0.92 · Close at T+90 US$0.57
- -37.5%Entry US$0.92 · Close at T+90 US$0.57
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate HeartBeam, Inc. Buy (bullish), based on 2 analysts. Average price target: US$3.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.48
Analyst consensus
2 analystsBuy
US$2.00Target US$3.50(+629%)US$5.00
Income statement
EBITDA-US$21.1M
Net income-US$21M0.0% margin
Valuation
P/Book3.3x
Beta-0.77
Balance sheet & cash
Market capUS$27.1M
Free Cash Flow-US$14.6M
Profitability & ownership
ROE-328.4%
ROA-153.5%
% insiders19.6%
% institutions14.4%
Last declaration on 24 July 2026
Declarations70 total
167,760 shares0Common StockSEC:0001213900-26-081455:0
2,800,000 shares0Common StockSEC:0001213900-26-081450:0
260,870 shares0Common StockSEC:0001213900-26-081450:1
105,740 shares0Common StockSEC:0001213900-26-081458:0
57,500 shares@ US$0.8030.2% of flowCommon StockSEC:0001213900-26-047514:0
Canonical exit: 15 Jul 2026 (T+90)
31,250 shares@ US$0.8042.5% of flowCommon StockSEC:0001213900-26-044841:0
Canonical exit: 15 Jul 2026 (T+90)
12,500 shares@ US$0.80100.0% of flowCommon StockSEC:0001213900-26-044834:0
Canonical exit: 15 Jul 2026 (T+90)
62,500 shares@ US$0.8032.8% of flowCommon StockSEC:0001213900-26-044835:0
Canonical exit: 15 Jul 2026 (T+90)
750,000 shares@ US$0.8040.1% of flowCommon StockSEC:0001213900-26-044832:0
Canonical exit: 15 Jul 2026 (T+90)
31,250 shares@ US$0.804.8% of flowCommon StockSEC:0001213900-26-044837:0
Canonical exit: 15 Jul 2026 (T+90)
31,250 shares@ US$0.80100.0% of flowCommon StockSEC:0001213900-26-044838:0
Canonical exit: 15 Jul 2026 (T+90)
187,500 shares@ US$0.80100.0% of flowCommon StockSEC:0001213900-26-044840:0
Canonical exit: 15 Jul 2026 (T+90)
25,000 shares@ US$0.8037.2% of flowCommon StockSEC:0001213900-26-044833:0
Canonical exit: 15 Jul 2026 (T+90)
20,689 shares0Common StockSEC:0001213900-26-033041:0
17,241 shares0Common StockSEC:0001213900-26-033029:0
50,000 shares0Common StockSEC:0001213900-26-033045:0
250,000 shares@ US$3.5859.9% of flowCommon StockSEC:0001213900-25-124693:0
23,961 shares@ US$3.6855.9% of flowCommon StockSEC:0001213900-25-123939:0
17,647 shares@ US$1.7057.5% of flowCommon StockSEC:0001628280-25-007239:0
Canonical exit: 15 May 2025 (T+90)
29,412 shares@ US$1.7037.0% of flowCommon StockSEC:0001628280-25-007240:0
Canonical exit: 15 May 2025 (T+90)
1,674 shares@ US$2.342.6% of flowCommon StockSEC:0001628280-24-040139:0
5,500 shares@ US$2.318.5% of flowCommon StockSEC:0001628280-24-039383:0
2,194 shares@ US$2.263.3% of flowCommon StockSEC:0001628280-24-038817:0
2,500 shares@ US$2.303.9% of flowCommon StockSEC:0001628280-24-038522:0
33,185 shares0Common StockSEC:0001779372-24-000014:0
25 of 70 declarations
About HeartBeam, Inc.
HeartBeam, Inc. is a U.S.-based medical technology company listed on NASDAQ in the United States. Founded in 2015 and incorporated in Delaware, the company is headquartered in Santa Clara, California. From an equity-research perspective, HeartBeam fits the profile of an early-commercial-stage medtech: a small-cap company moving from regulatory development toward first market adoption, with a valuation story driven more by product execution than by current scale. For French-, Belgian- and Swiss-based investors, the key investment thesis is straightforward: HeartBeam aims to make clinically meaningful ECG monitoring available outside the hospital through a portable, cable-free platform.
The company’s core business is built around proprietary 3D ECG technology. HeartBeam’s system captures cardiac electrical signals from three non-coplanar directions and uses software to synthesize a 12-lead ECG representation. The initial product is a credit-card-sized, cable-free device intended for symptom-driven recording at home or wherever the patient is located. This is designed to support arrhythmia assessment and broader cardiac monitoring, potentially helping shorten the time between symptoms and clinical interpretation. HeartBeam is also developing an extended-wear patch form factor, which suggests the platform could eventually expand beyond episodic use cases into more continuous monitoring applications.
Read moreShow less
Historically, HeartBeam spent several years in R&D and regulatory preparation before reaching its most important milestone. In December 2024, the company received FDA 510(k) clearance for the HeartBeam System for comprehensive arrhythmia assessment. In December 2025, it announced another FDA clearance for its 12-lead ECG synthesis software, strengthening the company’s pathway from product development to commercialization. By early 2026, HeartBeam said it was beginning a limited commercial launch, initially focusing on preventive cardiology, concierge medicine, and direct-pay channels in the U.S. market.
Competitive positioning is centered on product differentiation rather than scale. HeartBeam’s value proposition combines portability, patented technology, and the goal of delivering a 12-lead ECG outside the medical facility. That said, the company still faces the typical risks of an emerging medtech platform: customer adoption, reimbursement visibility, manufacturing and commercialization execution, and competition from established ambulatory monitoring and ECG players. The company also announced its first commercial customer, ClearCardio, in 2026, which is an important early validation of market interest, although commercial scale remains modest.
Geographically, HeartBeam’s operations are overwhelmingly U.S.-centric, with its headquarters and development base in California. For European investors, that means HeartBeam should be viewed as a high-risk, high-upside NASDAQ-listed U.S. healthcare technology name, with meaningful optionality if commercialization gains traction but substantial downside if adoption or funding progress disappoints. Recent highlights include FDA clearances, initial commercialization, clinical data presentations, and the first announced commercial customer, all of which mark a transition from development story to early go-to-market execution.
